We and others have demonstrated that class I HDAC inhibitors (HDACi), including the HDAC3-selective small molecule RGFP966, have disease-modifying potential when administered systemically in AD mouse models [8–10]. This evidence concerns the gene HDAC3 and Alzheimer disease.